Shots:

• The P-III BE OPTIMAL study evaluates bimekizumab vs PBO in 852 patients with active PsA who are biologic disease-modifying anti-rheumatic drug naïve
• The trial met its 1EPs & 2EPs  i.e., patients treated with bimekizumab achieved an improvement in signs & symptoms of the disease from baseline as measured by ACR 50 response (50% vs 20%) @16wks., improvements in physical function as measured by HAQ-DI; skin clearance as measured by 90% improvement in PASI 90; joint radiographic progression as measured by vdHmTSS @16wks.
• The safety profile was consistent with previous studies & no new safety signals were observed. The therapy is currently under US FDA’s review to treat PsO

Ref: PRNewswire | Image: UCB